Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675749 | 0.92 | SLC6A9 (0.46) | SLC6A9KCNH2CYP3A4MAOAMAOB | |
| SCHEMBL13736036 | 0.91 | SLC6A9 (0.66) | SLC6A9KCNH2CYP3A4 | |
| SCHEMBL17675761 | 0.89 | SLC6A9 (0.53) | SLC6A9KCNH2CYP3A4MAOAMAOB | |
| SCHEMBL13827326 | 0.85 | SLC6A9 (0.57) | SLC6A9KCNH2CYP3A4 | |
| SCHEMBL13738306 | 0.85 | SLC6A9 (0.39) | SLC6A9KCNH2 | |
| SCHEMBL7895627 | 0.82 | SLC6A9 (0.75) | SLC6A9KCNH2 | |
| SCHEMBL13827658 | 0.82 | SLC6A9 (0.47) | SLC6A9KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3098467 | 0.82 | SLC6A9 (0.73) | SLC6A9KCNH2 | |
| SCHEMBL13827332 | 0.82 | SLC6A9 (0.56) | SLC6A9KCNH2CYP3A4 | |
| SCHEMBL13827231 | 0.81 | SLC6A9 (0.59) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A11, SLC6A1, KCNB2 | SLC6A9 298/4885KCNH2 26/4885CYP3A4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.